OPDP has seen a major drop in enforcement letters, culminating in a record low of just five warning and untitled letters sent to Orexigen Therapeutics, Cipher Pharmaceuticals, Magna Pharmaceuticals, Avanthi and the University of California Los Angeles in 2017. While OPDP has issued two other untitled letters so far this year, it has not issued any warning letters to drugmakers over advertising and promotion related issues.